![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FTC Sets Conditions for Hikma’s Purchase of Roxane
FTC Sets Conditions for Hikma’s Purchase of Roxane
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
Jordanian drugmaker Hikma Pharmaceuticals will sell off two drugs and relinquish marketing rights to a third to avoid tangling with the Federal Trade Commission on its planned purchase of a Boehringer Ingelheim subsidiary.
In a proposed consent order issued last week, Hikma agreed to the commission’s terms to end antitrust litigation over its proposed acquisition of Roxane Laboratories, Boehringer’s generics unit, in a deal valued at roughly $2 billion.
The FTC’s complaint — which also was filed last week — alleges that the merger would improperly concentrate the markets for generic bipolar, inflammation and arrhythmia medications, leading to anticompetitive results.
Upcoming Events
-
21Oct